Invesco Ltd. Cor Medix Inc. Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Cor Medix Inc. stock. As of the latest transaction made, Invesco Ltd. holds 289,110 shares of CRMD stock, worth $3.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,110

Previous 24,703 1070.34%

Holding current value

$3.67 Million

Previous $200,000 790.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$6.16 - $12.57 $1.63 Million - $3.32 Million	264,407 Added 1070.34%	289,110 $1.78 Million
Q4 2024 Feb 13, 2025	BUY	$8.1 - $13.59 $30,650 - $51,424	3,784 Added 18.09%	24,703 $200,000
Q3 2024 Nov 12, 2024	SELL	$3.64 - $8.23 $2,296 - $5,193	-631 Reduced 2.93%	20,919 $169,000
Q2 2024 Aug 13, 2024	SELL	$4.08 - $6.39 $46,475 - $72,788	-11,391 Reduced 34.58%	21,550 $93,000
Q1 2024 May 14, 2024	BUY	$2.94 - $4.24 $10,337 - $14,907	3,516 Added 11.95%	32,941 $139,000
Q4 2023 Feb 12, 2024	SELL	$3.0 - $4.01 $83,892 - $112,135	-27,964 Reduced 48.73%	29,425 $110,000
Q3 2023 Nov 13, 2023	BUY	$3.6 - $4.46 $101,127 - $125,285	28,091 Added 95.88%	57,389 $212,000
Q2 2023 Aug 11, 2023	BUY	$3.94 - $5.8 $115,434 - $169,928	29,298 New	29,298 $116,000
Q2 2022 Aug 15, 2022	SELL	$2.73 - $5.61 $29,142 - $59,886	-10,675 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.83 - $6.24 $873 - $1,422	-228 Reduced 2.09%	10,675 $58,000
Q4 2021 Feb 14, 2022	SELL	$4.47 - $5.56 $5,189 - $6,455	-1,161 Reduced 9.62%	10,903 $50,000
Q3 2021 Nov 15, 2021	BUY	$4.46 - $7.11 $53,805 - $85,775	12,064 New	12,064 $56,000

Others Institutions Holding CRMD

# of Institutions

148

Shares Held

22.7M

Call Options Held

475K

Put Options Held

777K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $523M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account